Comparative Pharmacology
Head-to-head clinical analysis: DIPENTUM versus LIALDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIPENTUM versus LIALDA.
DIPENTUM vs LIALDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Olsalazine is a prodrug that is activated in the colon by bacterial azoreductases to release two molecules of 5-aminosalicylic acid (mesalamine), which locally inhibits cyclooxygenase and lipoxygenase pathways, reducing prostaglandin and leukotriene production, and exerts anti-inflammatory effects in the colonic mucosa.
Mesalamine, the active ingredient in Lialda, is an anti-inflammatory agent that inhibits prostaglandin production and leukotriene synthesis, and reduces cytokine production in the colonic mucosa.
500 mg orally twice daily, administered as two 250 mg capsules.
2-4 tablets (2.4-4.8 g) orally once daily. Each tablet contains 1.2 g mesalamine.
None Documented
None Documented
Terminal elimination half-life of olsalazine is approximately 0.9 hours. The active metabolite, 5-ASA, has a half-life in the colon of 2-5 hours due to local retention; systemic half-life is short (0.6-1.4 hours).
Terminal elimination half-life of mesalamine is approximately 12 hours (range 8-15 hours) for the sustained-release formulation; clinical steady-state is reached within 3-5 days.
Primarily renal (80%), with fecal/biliary excretion up to 20% as olsalazine and metabolites (mainly 5-ASA).
Renal (primarily, as N-acetyl-5-aminosalicylic acid, about 80%) and fecal (as unchanged mesalamine, about 20%).
Category C
Category C
Aminosalicylate
Aminosalicylate